Patents by Inventor Alireza Rezania

Alireza Rezania has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Universal donor cells
    Patent number: 11116797
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 14, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Universal donor cells
    Patent number: 11104918
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 31, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS
    Publication number: 20210171916
    Abstract: The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.
    Type: Application
    Filed: January 27, 2021
    Publication date: June 10, 2021
    Applicant: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Universal donor cells
    Patent number: 11008587
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: May 18, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Universal donor cells
    Patent number: 11008586
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: May 18, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • UNIVERSAL DONOR CELLS
    Publication number: 20210115471
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Application
    Filed: July 14, 2020
    Publication date: April 22, 2021
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS
    Publication number: 20210079353
    Abstract: The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells of a mature phenotype. The resulting pancreatic endocrine cells express single hormonal insulin, PDX1, NKX6.1, and MAFA. In one or more differentiation stages, culturing may be carried out in a culture vessel at the air-liquid interface.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Applicant: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptor
    Patent number: 10947511
    Abstract: The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 16, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • UNIVERSAL DONOR CELLS
    Publication number: 20210070835
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Alireza REZANIA, Rebeca RAMOS-ZAYAS
  • UNIVERSAL DONOR CELLS
    Publication number: 20210070836
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Alireza REZANIA, Rebeca Ramos-Zayas
  • UNIVERSAL DONOR CELLS
    Publication number: 20210071201
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Alireza REZANIA, Rebeca RAMOS-ZAYAS
  • UNIVERSAL DONOR CELLS
    Publication number: 20210069256
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: ALIREZA REZANIA, REBECA RAMOS-ZAYAS
  • UNIVERSAL DONOR CELLS
    Publication number: 20210070837
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Alireza REZANIA, Rebeca RAMOS-ZAYAS
  • Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
    Patent number: 10870832
    Abstract: The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells of a mature phenotype. The resulting pancreatic endocrine cells express single hormonal insulin, PDX1, NKX6.1, and MAFA. In one or more differentiation stages, culturing may be carried out in a culture vessel at the air-liquid interface.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 22, 2020
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Universal donor cells
    Patent number: 10865424
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: December 15, 2020
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • UNIVERSAL DONOR CELLS
    Publication number: 20200347403
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Application
    Filed: July 14, 2020
    Publication date: November 5, 2020
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • UNIVERSAL DONOR CELLS
    Publication number: 20200347411
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Application
    Filed: July 14, 2020
    Publication date: November 5, 2020
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Universal donor cells
    Patent number: 10724052
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: July 28, 2020
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE
    Publication number: 20200208116
    Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Applicant: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania
  • Methods for production of functional beta cells
    Patent number: 10633635
    Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 28, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania